Biotech

Biotech By Matthew Herper

Data fuel debate over whether J&J’s one-dose Covid vaccine will measure up

Biotech By Matthew Herper

Virtual Event: [email protected]: Facing 2021

Biotech By Kate Sheridan

Sana Biotechnology, filing for IPO, aims for astronomical valuation

Biotech By Damian Garde

What if a pill could lower cholesterol like pricey injectables? Esperion intends to find out

Biotech By Kate Sheridan and Adam Feuerstein

After repeated FDA rejections, key investor writes down stake in former diabetes unicorn Intarcia Therapeutics 

Biotech By Adam Feuerstein

With durable monkey data, Verve selects its first CRISPR base editing treatment for human trials

Biotech By Adam Feuerstein and Matthew Herper

Gilead’s remdesivir sales are surging, but investors aren’t impressed

Biotech By Damian Garde

Lilly’s preliminary Alzheimer’s data adds $4 billion to Biogen’s value

Biotech By Adam Feuerstein

Vertex Pharma taking more aggressive M&A stance, flush with cash from cystic fibrosis drugs

Biotech By Adam Feuerstein

Bluebird Bio intends to split into two companies, but for now, its troubles are also divided

Exclusive By Matthew Herper

Tempus unveils prototype cube that talks back to oncologists

Biotech By Matthew Herper

Company dedicated to cutting drug prices raises lots of money, releases few details

Biotech By Matthew Herper

Eli Lilly says drug slowed Alzheimer’s decline in preliminary study

Biotech By Adam Feuerstein

Sarepta gene therapy for Duchenne muscular dystrophy stumbles with failed study outcome

Biotech By Anissa Gardizy — Boston Globe

With biotech funding at ‘all-time high,’ Scorpion scoops up $162 million

Biotech By Matthew Herper

Serial biotech entrepreneur John Hood raises $62 million for company aimed at deadly lung disease

In the Lab By Sharon Begley

CRISPR cures progeria in mice, raising hope for one-time therapy for a disease that causes rapid aging

Biotech By Kate Sheridan

Siddhartha Mukherjee forms his second biotech company, focused on using cell therapy for solid tumors

Biotech By Adam Feuerstein

The biotech scorecard for the first quarter: 17 stock-moving events to watch

Biotech By Adam Feuerstein and Damian Garde

The biotech 2021 preview, from M&A to gene therapy and more

Biotech By Kate Sheridan

3 biotech trends to watch in 2021

First Opinion By Shirley Leung

‘There are a lot of potential Modernas’: The ‘Massachusetts Miracle’ is alive and well

Biotech By Damian Garde

How 2020 became the year of the biotech SPAC

Biotech By Damian Garde

STAT+ Conversations: A conversation with Nobel laureate Charles Rice

Biotech By Kate Sheridan

The most impressive biotech VCs of 2020 

Biotech By Adam Feuerstein

Uniqure’s hemophilia B gene therapy program on hold due to cancer diagnosis in treated patient

Biotech By Adam Feuerstein

Agios sells cancer business to French drug maker for up to $2 billion, will now focus on inherited diseases

Adam's Take By Adam Feuerstein

Kulkarni victorious in best biopharma CEO vote; Leschly tops worst list

Biotech By Matthew Herper

Virtual Event: A look ahead at biotech in 2021